Christine Posted August 29, 2007 Share Posted August 29, 2007 FRANKFURT (Thomson Financial) - Merck KGaA said its division Merck Serono's Phase II trial of Matuzumab to treat metastatic colorectal cancer (mCRC) did not meet its predefined endpoint, adding it is 'reconsidering' further development of the drug. Matuzumab is being co-developed and co-commercialised jointly by Merck Serono and Takeda. 'Both companies share the view that the study results in mCRC do not meet expectations,' Merck said. However the two companies will continue to study the drug in other tumours, including non-small cell lung cancer Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.